Nykode Therapeutics ASA Logo

Nykode Therapeutics ASA

NYKD | OL

Overview

Corporate Details

ISIN(s):
NO0010714785
LEI:
254900UKQHWYZJD22017
Country:
Norway
Address:
Gaustadalleen 21, 0349 Oslo
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies and vaccines. The company's core technology is its proprietary and modular Vaccibody™ platform, designed to elicit fast, strong, and long-lasting immune responses by targeting antigens to Antigen Presenting Cells. This pioneering approach is being applied to develop treatments for a wide range of diseases, with a primary focus on cancer and infectious diseases. The platform's modularity and tailored hyper-targeting capabilities are key differentiators, offering a versatile foundation for creating next-generation medicines.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Nykode Therapeutics ASA. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-09 18:15
Director's Dealing
Nykode Therapeutics – Grant of Share Options - Attachment: Attachment 250709.pdf
English 213.3 KB
2025-07-09 18:15
Remuneration Information
Nykode Therapeutics – Grant of Share Options
English 1.1 KB
2025-07-04 16:41
Report Publication Announcement
Financial calendar
English 508 bytes
2025-05-28 07:00
Quarterly Report
Nykode Therapeutics - Quarterly report Q1 2025 - Attachment: 250528 Nykode Quar…
English 4.3 MB
2025-05-28 07:00
Report Publication Announcement
Nykode Therapeutics - Quarterly report Q1 2025
English 3.0 KB
2025-05-27 07:00
Notice of Dividend Amount
Nykode Therapeutics ASA - Ex-dividend NOK 1.00 today
English 490 bytes
2025-05-26 16:51
Report Publication Announcement
Nykode Therapeutics – invitation to Q1 2025 financial results presentation - A…
English 125.5 KB
2025-05-26 16:51
Report Publication Announcement
Nykode Therapeutics – invitation to Q1 2025 financial results presentation
English 3.2 KB
2025-05-26 11:25
Post-Annual General Meeting Information
Nykode Therapeutics ASA - Minutes of Annual General Meeting - Attachment: 25052…
English 297.9 KB
2025-05-26 11:25
Post-Annual General Meeting Information
Nykode Therapeutics ASA - Minutes of Annual General Meeting
English 2.8 KB
2025-05-23 05:00
Investor Presentation
Nykode Therapeutics Highlights New Data in Two Poster Presentations at the 2025…
English 176.1 KB
2025-05-23 05:00
Regulatory News Service
Nykode Therapeutics Highlights New Data in Two Poster Presentations at the 2025…
English 6.4 KB
2025-05-05 06:30
Pre-Annual General Meeting Information
Nykode Therapeutics ASA - Notice of Annual General Meeting
Norwegian 319.2 KB
2025-05-05 06:30
Pre-Annual General Meeting Information
Nykode Therapeutics ASA - Notice of Annual General Meeting
English 1.0 KB
2025-04-29 05:00
Annual Report (ESEF)
Nykode Therapeutics - Annual Report 2024
English 17.1 MB

Automate Your Workflow. Get a real-time feed of all Nykode Therapeutics ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Nykode Therapeutics ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
VERICI DX PLC Logo
AI-powered diagnostic tests for the kidney transplant market, predicting organ rejection and injury.
United Kingdom VRCI
Vicore Pharma Holding Logo
Develops AT2 receptor drugs and a digital therapeutic for pulmonary fibrosis.
Sweden VICO
Vivoryon Therapeutics N.V. Logo
Develops small molecule therapies for severe age-related, inflammatory, and neurodegenerative diseases.
Germany VVY
R&D in renewable energy & manufacturing specialized tools for automotive & engineering.
Slovakia N/A
Xintela AB Logo
Develops stem cell therapies and targeted antibody treatments for cancer and osteoarthritis.
Sweden XINT
Xlife Sciences AG Logo
A life sciences incubator commercializing early-stage academic research for healthcare markets.
Switzerland XLS
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage therapeutics for autoimmune diseases.
Israel XTLB
Yoshi Innovation Spolka Akcyjna Logo
A tech fund incubating MedTech, biotech, and defense ventures with investment and IP protection.
Poland YOS
Zealand Pharma Logo
Develops innovative peptide medicines for metabolic and rare diseases.
Denmark ZEAL
Ziccum AB Logo
Licenses drying tech for thermostable vaccines & biologics, eliminating the cold chain.
Sweden ZICC